Dogwood Therapeutics, Inc.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$34.3M
- Total assets
- $90.2M
- Market cap
- $50.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $28.0M
- Operating income
- -$28.0M
- Income tax
- $221.1K
- Net income
- -$34.3M
- EPS (basic)
- $-7.13
- EPS (diluted)
- $-7.13
Balance sheet
- Total assets
- $90.2M
- Current assets
- $8.4M
- Total liabilities
- $15.3M
- Current liabilities
- $3.1M
- Shareholders’ equity
- $74.9M
Cash flow
- Operating cash flow
- -$15.6M
- Investing cash flow
- $8.3M
- Financing cash flow
- $7.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $50.4M
- EPS (diluted)
- $-7.13
- Shares outstanding
- 34.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 17, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $34.3M.
- Trading 82% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dogwood Therapeutics, Inc..
Write a review
News about Dogwood Therapeutics, Inc.
News & sentiment via Polygon.io
